You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 17, 2026

Drug Price Trends for HM DAY SEVERE COLD-FLU CAPLET


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for HM DAY SEVERE COLD-FLU CAPLET

Average Pharmacy Cost for HM DAY SEVERE COLD-FLU CAPLET

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
HM DAY SEVERE COLD-FLU CAPLET 62011-0406-01 0.13926 EACH 2025-04-23
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Market Analysis and Price Projections for HM DAY SEVERE COLD-FLU CAPLET

Last updated: February 27, 2026

What is the Current Market Position of HM DAY SEVERE COLD-FLU CAPLET?

HM DAY SEVERE COLD-FLU CAPLET targets the over-the-counter (OTC) cold and flu medication segment. It competes primarily with products like NyQuil, DayQuil, and Tylenol Cold, which are established brands with significant market share. The product’s active ingredients typically include acetaminophen, dextromethorphan, and phenylephrine, aligning with common formulations for cold and flu relief.

Market Size and Trends

  • The global cold and flu remedy market was valued at USD 10.8 billion in 2022.
  • It is projected to reach USD 13.5 billion by 2027, growing at a compound annual growth rate (CAGR) of 4.6% (Research and Markets, 2022).
  • The OTC segment accounts for approximately 80% of the market, with OTC cold remedies constituting about USD 8.6 billion globally (Grand View Research, 2022).

Competitive Landscape

Major players include:

Company Market Share (Estimated) Key Products
Johnson & Johnson 25% Tylenol Cold, Zyrtec
Procter & Gamble 20% NyQuil, DayQuil
GlaxoSmithKline 15% Panadol Cold & Flu
Others 40% Various regional and generic brands

HM Day Severe Cold-Flu Caplet positions itself as a budget-friendly, multi-symptom alternative, leveraging active ingredients comparable to market leaders.

Who Are the Main Consumer Segments?

  • Adults seeking self-care for cold and flu.
  • Consumers aged 25-45, with a preference for quick relief.
  • Price-sensitive buyers favoring store brands.

How Does Pricing Compare?

Brand Price Range (USD) per packet Packaging Size
HM DAY SEVERE COLD-FLU CAPLET $4.50 – $6.00 10–12 caplets per pack
NyQuil/DayQuil $6.00 – $8.50 12–16 caplets
Tylenol Cold $5.50 – $7.50 10–20 caplets
Store Brands $3.50 – $5.50 10–12 caplets

HM Day is priced slightly below premium brands but above generics, indicating positioning as an affordable mid-tier product.

Price Projections and Market Growth Factors

Short-term (Next 1–2 years)

  • Price stability expected due to established supply chains and consumer familiarity.
  • Minimal discounts or promotions projected, as brand recognition increases.
  • Anticipated retail price: USD 4.75 to USD 6.25 per pack.

Mid-term (3–5 years)

  • Slight price increases aligned with inflation and ingredient cost hikes—expected 3%–5% annually.
  • Introduction of larger packs or combo offerings could expand sales volumes without raising per-unit prices.
  • Possible premium positioning if formulation enhancements occur.

Long-term (5+ years)

  • Market maturity may pressure prices downward due to increased generic competition.
  • Price range projected: USD 4.50–USD 6.50 per pack.
  • Market share shifts may influence pricing strategies, particularly if new entrants or formulations disrupt existing brands.

Key Factors Influencing Price Trends:

  • Ingredient cost fluctuations, especially for dextromethorphan and phenylephrine.
  • Regulatory changes affecting labeling or formulation.
  • Retailer promotional strategies and private label incursions.
  • Consumer health awareness driving preference for proven products.

Regulatory and Supply Chain Considerations

  • As an OTC drug, domestic and international regulatory compliance influences formulation and packaging.
  • Regulatory changes, such as limits on phenylephrine doses, could impact formulation and, consequently, pricing.
  • Supply chain disruptions for active ingredients could lead to supply shortages, affecting pricing and availability.

Final Analysis

HM Day Severe Cold-Flu Caplet occupies a competitive mid-tier position, offering a cost-effective alternative with stable pricing expectations. Its growth prospects depend largely on market penetration, consumer trust, and competitive dynamics with established brands.


Key Takeaways

  • The global OTC cold and flu market is expanding, with a CAGR of about 4.6%, expected to reach USD 13.5 billion by 2027.
  • HM Day is priced slightly below premium brands but above generics—USD 4.50 to USD 6.25 per pack.
  • Short-term prices remain stable; mid-term projections suggest slight increases due to inflation and supply costs.
  • Long-term competition and regulatory shifts could pressure prices downward.
  • Market growth hinges on consumer preferences, formulation efficacy, and distribution channels.

FAQ

1. What ingredients are in HM Day Severe Cold-Flu Caplet?
Typically, it contains acetaminophen (pain reliever/fever reducer), dextromethorphan (cough suppressant), and phenylephrine (decongestant).

2. How does HM Day compare with major brands?
It offers similar symptom relief at a lower price point, targeting price-sensitive consumers without compromising on formulation.

3. What are the growth drivers for this product?
Increasing demand for OTC remedies, seasonal cold and flu outbreaks, and consumer shift toward self-care.

4. Are there regulatory risks affecting pricing?
Yes. Changes in ingredient approval or dosage limits could necessitate reformulation, impacting production costs and prices.

5. What factors could lead to price reductions in the future?
Entry of competitors, generic market expansion, and regulatory constraints decreasing formulation costs or increasing competition.


References

[1] Research and Markets. (2022). Cold and Flu Remedy Market Report.
[2] Grand View Research. (2022). OTC Cold and Flu Medication Market Size & Trends.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.